The nuclear receptor known as the androgen receptor (AR) is activated when either the androgenic hormones testosterone or dihydrotestosterone bind to it in the cytoplasm before moving into the nucleus. The receptor separates from supporting proteins after binding the hormone ligand, moves into the nucleus, dimerizes, and then activates transcription of androgen-responsive genes. The progesterone receptor is most similar to the androgen receptor, and progestins can block the androgen receptor when used in higher doses. The androgen receptor's primary role is that of a DNA-binding transcription factor that controls gene expression. The development and maintenance of the male sexual phenotype depend heavily on genes that are regulated by androgen. Complete androgen insensitivity (CAIS) is a condition that is also correlated with mutations in this gene.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V107606 | Trestolone acetate | 6157-87-5 | Tritolon acetate is an androgenic steroid. |
|
V3752 | UT-155 | 2031161-35-8 | UT-155 is a potent and selective androgen receptor (AR) degrader (SARD) that markedly reduces the activity of wild-type and splice variant isoforms of AR at submicromolar doses. |
|
V38848 | UT-34 | 2168525-92-4 | UT-34 (UT34) is a novel, selective, and orally bioavailable pan-androgen receptor (AR) antagonist and also aselective androgen receptor degrader (SARD)with anti-prostate cancer activity. |
|
V88171 | VinclozolinM2-2204 | VinclozolinM2-2204 is an androgen receptor degrader with a DC50 of 200 nM in LNCaP prostate cancer cells. | |
|
V88978 | VNPP433-3β | 1630820-51-7 | VNPP433-3β is a molecular glue degrader that targets androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinases Mnk1/2. |
|
V4069 | Testolone (RAD140) | 1182367-47-0 | Testolone (formerly known as RAD140) is a novel, potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM) that is being investigated for the treatment of conditions such as muscle wasting and breast cancer. |
|
V50982 | WAY-324106 | 1351506-85-8 | androgen receptor modulator |
|
V50997 | WAY-324109 | 1351360-79-6 | androgen receptor modulator |
|
V51003 | WAY-621998 | 743475-40-3 | androgen Receptor modulator |
|
V4072 | YK11 DEA controlled substance | 1370003-76-1 | YK-11 is a novel, potent, synthetic, steroidal selective androgen receptor modulator (SARM) that acts as a partial agonist of androgen receptor with osteogenic activity. |
|
V89075 | Zanoterone | 107000-34-0 | Zanoterone is an orally available androgen receptor (AR) antagonist (Ki=2.2 μM). |
|
V13466 | Clascoterone | 19608-29-8 | Clascoterone (cortexolone 17alpha-propionate; CB-03-01; Winlevi; Breezula) is a novel and potent androgen antagonist that has been approved in 2020 for topical use in the treatment of acne. |
|
V4725 | Dimethylcurcumin | 52328-98-0 | Dimethylcurcumin (formerly known as ASC-J9; GO-Y025) is anandrogen receptor(AR)degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion. |
|
V1757 | Enzalutamide (MDV3100) | 915087-33-1 | Enzalutamide (formerly MDV3100;MDV-3100; trade name: Xtandi) is an orally bioavailable, 2nd-generation and non-steroidal androgen-receptor (AR) antagonist with potential antineoplastic activity. |
|
V7564 | Proxalutamide | 1398046-21-3 | Proxalutamide (GT0918;GT-0918) is a novel, oral and potent androgen receptor/AR antagonist or nonsteroidal antiandrogen (NSAA). |
|
V1758 | Bicalutamide (Casodex; ICI-176334) | 90357-06-5 | Bicalutamide (formerly known as ICI-176334; CDX; trade names: Casodex in the USA and Cosudex in other countries), a marketed drug for treating PC (prostate cancer), is a potent, synthetic, nonsteroidalandrogen receptor (AR) antagonist with potential anticancer activity. |
|
V1764 | Flutamide (SCH 13521) | 13311-84-7 | Flutamide (also known as SCH13521; SCH-13521; trade names: Flucinom; Flugerel; Niftolid;Flutan;Oncosal etc. |
|
V1768 | Cyproterone Acetate | 427-51-0 | Cyproterone acetate (Cyprone, Androcur, Cyprostat,Cyprohexal, Ciproterona, Cyproteron, Procur,Cyproteronum, Neoproxil, Siterone), an analog of17-hydroxyprogesterone, is an androgen receptor (AR) antagonist with potential antitumor activity. |
|
V1770 | Spironolactone (SC9420) DEA controlled substance | 52-01-7 | Spironolactone(SC9420; SC-9420; SC 9420; Spiresis; Spiridon) is a potent androgen receptor/AR antagonist with potential antineoplastic activity. |
|
V1767 | Epiandrosterone | 481-29-8 | Epiandrosterone [also known as 3β-androsterone, Epi (17-ketosteroid epiandrosterone)]is a naturally occuring/endogenous steroid hormone with weak androgenic activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
